Firm’s Magellan MAR01 and Nanex platforms will be tested for point-of-care capabilities.

Arteriocyte entered into a three-year CRADA with the United States Army Institute of Surgical Research (USAISR) to investigate stem cell therapies developed on the company’s technologies for orthopedic trauma and related battlefield injuries. Arteriocyte’s Magellan® MAR01™ system will be evaluated for bedside production of cellular therapies and its Nanex™ platform will be used for stem cell expansion.

Arteriocyte is currently working with USAISR to evaluate Magellan point-of-care therapies for compartment syndrome (amputation prevention), burn debridement, and post-surgical wound infection prevention. The newly established CRADA will enable Arteriocyte to work directly with USAISR staff to explore broader use of its technologies to treat orthopedic trauma including limb injuries (bone, cartilage, muscle, and vessel structure) that affect a majority of battlefield wounded soldiers.

The Magellan system is an FDA 510(k)-cleared medical device for the rapid production of platelet-rich plasma from blood and bone marrow that is applied to a surgical site. Magellan MAR01 technology enables the closed-system concentration of aspirated bone marrow, yielding an injectable tissue rich in platelets, hematopoietic stem cells, and mesenchymal stem cells, commonly viewed as key components in tissue repair.

The self-contained Magellan unit provides ease-of-use and operator-independent consistency necessary for deployment in military medical operations, according to Arteriocyte. In addition to therapies for battlefield wounds, Arteriocyte is currently enrolling patients into a Phase I trial to evaluate the role of MAR01 in peripheral vascular disease with additional cardiac and orthopedic trials planned.

The Nanex platform consists of a biofunctional nanofiber-based 3-D scaffold designed to mimic the bone marrow environment, permitting rapid ex vivo proliferation of hematopoietic stem cells with minimal differentiation. Arteriocyte has multiple active development programs for this platform, including treatment of ischemic disease, identification and treatment of cancers of the blood system, and high-volume ex vivo red blood cell production.

Previous articleLeukemia & Lymphoma Society Inks Four Deals to Advance Research into the Clinic
Next articleLonza Eyes CHF 10M Expansion of Singapore Biopharmaceutical Development Facility